Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Crinetics Pharmaceuticals, Inc.CRNX · Entity 3579 | Chief Medical Officer | October 17, 2023 | October 19, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Crinetics Pharmaceuticals, Inc.
Report date October 17, 2023 · Filed October 19, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 50,210 |
Reported balance
After 2023-10-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-10-17 · Exercise / conversion · Acquired 7,000 · Balance 50,210 F1: Includes 909 shares acquired under the Issuer's Employee Stock Purchase Plan since the last Section 16 filing by the Reporting Person. |
| Common StockSEC Table I · non-derivative | Direct | 43,210 |
Reported balance
After 2023-10-17 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-10-17 · Sale · Disposed 7,000 · Balance 43,210 |
| Non-qualified stock option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.01 · Expires 2028-06-15 | Direct | 153,473 |
Reported balance
After 2023-10-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-10-17 · Exercise / conversion · Disposed 7,000 · Balance 153,473 F2: 25% of the shares subject to the option vest on June 16, 2019, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. The stock options are also subject to accelerated vesting as set forth in the employment agreement between the Issuer and the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 909 shares acquired under the Issuer's Employee Stock Purchase Plan since the last Section 16 filing by the Reporting Person.
F2: 25% of the shares subject to the option vest on June 16, 2019, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. The stock options are also subject to accelerated vesting as set forth in the employment agreement between the Issuer and the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 17, 2023 Filed Oct 19, 2023 21:01 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionNon-qualified stock option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $12.01 | $0.00 |
DisclosureSEC source: 0001209191-23-053186 · doc4.xml · derivative · entry 3 Krasner Alan Seth · CIK 0001435775 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,473 Underlying: Common Stock · 7,000 shares Expires 2028-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the option vest on June 16, 2019, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. The stock options are also subject to accelerated vesting as set forth in the employment agreement between the Issuer and the Reporting Person. Read SEC document |
| October 17, 2023 Filed Oct 19, 2023 21:01 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 7,000 | $30.00 | $210,000.00 |
DisclosureSEC source: 0001209191-23-053186 · doc4.xml · nonDerivative · entry 2 Krasner Alan Seth · CIK 0001435775 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,210 Read SEC document |
| October 17, 2023 Filed Oct 19, 2023 21:01 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionCommon Stock | 7,000 | $12.01 | $84,070.00 |
DisclosureSEC source: 0001209191-23-053186 · doc4.xml · nonDerivative · entry 1 Krasner Alan Seth · CIK 0001435775 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 909 shares acquired under the Issuer's Employee Stock Purchase Plan since the last Section 16 filing by the Reporting Person. Read SEC document |
| March 16, 2023 Filed Mar 17, 2023 21:09 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Tax withholdingCommon Stock | 1,687 | $17.12 | $28,881.44 |
DisclosureSEC source: 0001209191-23-019770 · doc4.xml · nonDerivative · entry 1 Krasner Alan Seth · CIK 0001435775 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,301 F1 · kind: Represents the number of shares of common stock withheld by the Issuer to cover the reporting person's tax withholding obligation upon the vesting of Restricted Stock Units granted on February 28, 2022. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:43 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantCommon Stock (right to buy) · Derivative | 91,000 | $0.00 Strike: $19.64 | $0.00 |
DisclosureSEC source: 0001209191-23-015598 · doc4.xml · derivative · entry 2 Krasner Alan Seth · CIK 0001435775 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,000 Underlying: Common Stock · 91,000 shares Expires 2033-02-28 F2 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of March 1, 2023. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:43 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantCommon Stock | 19,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-015598 · doc4.xml · nonDerivative · entry 1 Krasner Alan Seth · CIK 0001435775 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,988 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2024. Read SEC document |
| November 20, 2022 Filed Jan 27, 2023 21:28 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | OtherCommon Stock | 712 | $11.02 | $7,846.24 |
DisclosureSEC source: 0001209191-23-005254 · doc5.xml · nonDerivative · entry 2 Krasner Alan Seth · CIK 0001435775 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,488 F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c), Read SEC document |
| May 20, 2022 Filed Jan 27, 2023 21:28 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | OtherCommon Stock | 1,215 | $11.02 | $13,389.30 |
DisclosureSEC source: 0001209191-23-005254 · doc5.xml · nonDerivative · entry 1 Krasner Alan Seth · CIK 0001435775 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,776 F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c), Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:00 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantCommon Stock (right to buy) · Derivative | 66,500 | $0.00 Strike: $20.02 | $0.00 |
DisclosureSEC source: 0001209191-22-015129 · doc4.xml · derivative · entry 2 Krasner Alan Seth · CIK 0001435775 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,500 Underlying: Common Stock · 66,500 shares Expires 2032-02-27 F2 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 28, 2022. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:00 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantCommon Stock | 14,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015129 · doc4.xml · nonDerivative · entry 1 Krasner Alan Seth · CIK 0001435775 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,561 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2023. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:54 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionNon-qualified stock option (Right to Buy) · Derivative | 6,700 | $0.00 Strike: $12.01 | $0.00 |
DisclosureSEC source: 0001209191-22-004453 · doc4.xml · derivative · entry 3 Krasner Alan Seth · CIK 0001435775 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,473 Underlying: Common stock · 6,700 shares Expires 2028-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. F4 · derivative.exercise_date: Stock option granted June 16, 2018 with 25% vesting on the first anniversary of the grant date and the remainder vesting in a series of thirty-six (36) successive equal monthly installments thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:54 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 6,700 | $21.21 | $142,080.20 |
DisclosureSEC source: 0001209191-22-004453 · doc4.xml · nonDerivative · entry 2 Krasner Alan Seth · CIK 0001435775 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,311 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sales prices range between $20.77 and $21.68. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:54 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionCommon Stock | 6,700 | $12.01 | $80,467.00 |
DisclosureSEC source: 0001209191-22-004453 · doc4.xml · nonDerivative · entry 1 Krasner Alan Seth · CIK 0001435775 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,011 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. F2 · balance_after: Includes 1,928 shares acquired under the Issuer's Employee Stock Purchase Plan since the last Section 16 filing by the Reporting Person. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 22:27 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $15.29 | $0.00 |
DisclosureSEC source: 0001209191-21-016288 · doc4.xml · derivative · entry 1 Krasner Alan Seth · CIK 0001435775 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-02-25 F1 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 26, 2021. Read SEC document |
| November 20, 2020 Filed Feb 5, 2021 21:46 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | OtherCommon Stock | 277 | $11.61 | $3,215.97 |
DisclosureSEC source: 0001209191-21-008108 · doc5.xml · nonDerivative · entry 2 Krasner Alan Seth · CIK 0001435775 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,383 F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c), Read SEC document |
| May 20, 2020 Filed Feb 5, 2021 21:46 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | OtherCommon Stock | 1,165 | $14.45 | $16,834.25 |
DisclosureSEC source: 0001209191-21-008108 · doc5.xml · nonDerivative · entry 1 Krasner Alan Seth · CIK 0001435775 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,106 F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c), Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:18 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $22.61 | $0.00 |
DisclosureSEC source: 0001209191-20-012997 · doc4.xml · derivative · entry 1 Krasner Alan Seth · CIK 0001435775 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2030-02-23 F1 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 24, 2020. Read SEC document |
| May 20, 2019 Filed Feb 11, 2020 21:06 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | OtherCommon Stock | 1,471 | $14.45 | $21,255.95 |
DisclosureSEC source: 0001209191-20-008272 · doc5.xml · nonDerivative · entry 1 Krasner Alan Seth · CIK 0001435775 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,941 F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c). Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 22:42 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 56,250 | $0.00 Strike: $25.19 | $0.00 |
DisclosureSEC source: 0001209191-19-018982 · doc4.xml · derivative · entry 1 Krasner Alan Seth · CIK 0001435775 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Stock · 56,250 shares Expires 2029-03-07 F1 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the Vesting Commencement Date of March 8, 2019. Read SEC document |
| November 20, 2018 Filed Feb 12, 2019 22:25 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | OtherCommon Stock | 1,470 | $14.45 | $21,241.50 |
DisclosureSEC source: 0000899243-19-003318 · doc5.xml · nonDerivative · entry 1 Krasner Alan Seth · CIK 0001435775 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,470 F1 · kind: Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c). Read SEC document |
| July 20, 2018 Filed Jul 20, 2018 20:06 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | PurchaseCommon Stock | 2,000 | $17.00 | $34,000.00 |
DisclosureSEC source: 0000899243-18-020264 · doc4.xml · nonDerivative · entry 1 Krasner Alan Seth · CIK 0001435775 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.